-transparent.png){kind=logo}
The most feared side-effect of long-term amiodarone therapy is progressive alveolitis/pneumonitis leading to pulmonary fibrosis. The case history of a patient is presented who received amiodarone unnecessarily in a high dose (600 mg/day) for 4 years: drug-induced dermatopathy, hypothyroidism and lung fibrosis developed. After cessation of amiodarone treatment the pulmonary complication did not disappear therefore glucocorticoid therapy was introduced. New-onset improductive cough, dyspnea, fever and/or enhanced erythrocyte sedimentation rate may suggest the presence of amiodarone pulmonary toxicity and may form the basis of indication of high-resolution computed tomography (HRCT). Amiodarone-induced pulmonary involvement can be shown by HRCT early, before the appearance of any considerable abnormality of chest radiography.
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
January 1997,
Orvosi hetilap,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
January 1985,
Revista medica de Chile,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
January 1984,
Revista espanola de cardiologia,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
October 2000,
Intensive care medicine,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
August 1998,
Pacing and clinical electrophysiology : PACE,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
January 1984,
Experimental lung research,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
January 2006,
Revista portuguesa de pneumologia,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
October 2015,
The journal of pathology. Clinical research,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
June 1996,
Toxicology,
C Lengyel, and
I Boros, and
T Várkonyi, and
A Selmeczi, and
T Fazekas
September 1982,
British medical journal (Clinical research ed.),
